breast cancer

Research in Review

Trastuzumab Emtansine Improves OS in Patients With HER2+ Breast Cancer

05/19/2017

JCP Editors

Patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer benefit from an estimated 7 additional months of survival if treated with trastuzumab emtansine rather than the physician’s choice...

...

05/19/2017

Journal of Clinical Pathways

Research in Review

MRI Results After DCIS Biopsy Unreliable, Leads to Overtreatment

05/04/2017

JCP Editors

MRI results after percutaneous biopsy for ductal carcinoma in situ (DCIS) often overestimate the extent of breast cancer, resulting in unnecessary mastectomies, according to a presentation at the American Society of...

MRI...

05/04/2017

Journal of Clinical Pathways

Research in Review

Bone Model Examines Treatment Effectiveness for Breast Cancer Metastases

04/24/2017

JCP Editors

A bone metastasis model has been created that simulates interactions between metastatic breast cancer cells and bone cells to determine effectiveness of different treatments, published in Nature Communications...

A bone...

04/24/2017

Journal of Clinical Pathways

Research in Review

Cost-Effectiveness of Early-Stage Breast Cancer Treatment Options Vary Significantly

04/21/2017

JCP Editors

Certain therapy options for early-stage breast cancer have fewer associated complications and are much less expensive than others, according to a study published in the Journal of the National Cancer Institute...

...

04/21/2017

Journal of Clinical Pathways

Research in Review

Palbociclib Plus Fulvestrant Improves PFS in Type of Breast Cancer

04/19/2017

JCP Editors

Adding palbociclib to fulvestrant prolongs progression-free survival (PFS) compared with fulvestrant alone among pre- and post-menopausal women with hormone receptor (HR)-positive, human epidermal growth factor...

Adding...

04/19/2017

Journal of Clinical Pathways

Research in Review

Body Composition Impacts Chemo Toxicity for Patients With Breast Cancer

03/07/2017

JCP Editors

Using body composition metrics to determine dosage of anthracyclines-taxane based chemotherapy for patients with breast cancer can reduce treatment-related toxicity, according to a study published in Clinical Cancer...

Using...

03/07/2017

Journal of Clinical Pathways

Research in Review

Women Treated for Precursor of Breast Cancer Live Longer Than Other Women

01/27/2017

JCP Editors

Women aged 50 years or older who have been treated for ductal carcinoma in situ (DCIS) are likely to live longer than women in the general population, according to a presentation at the European Cancer Congress...

Women...

01/27/2017

Journal of Clinical Pathways

Research in Review

Comparative Effectiveness Report Favors Aromatase Inhibitors Over Tamoxifen for Early-Stage Breast Cancer

01/04/2017

JCP Editors

Treatment with aromatase inhibitors improves outcomes versus treatment with tamoxifen for patients with early-stage breast cancer, according to a report published by the German Institute for Quality and Efficiency in...

...

01/04/2017

Journal of Clinical Pathways

Research in Review

Precision Medicine Increasingly Guides Decision-Making for Patients with Breast Cancer

12/29/2016

JCP Editors

Breast cancer serves as a model for using precision medicine to guide treatment decisions and improve patients’ quality of life, according to a presentation at the 2016 Lynn Sage Breast Cancer...

Breast...

12/29/2016

Journal of Clinical Pathways

Research in Review

Menopausal Symptoms Wrongly Attributed to Tamoxifen Dampen Adherence Rates

12/13/2016

JCP Editors

Menapausal symptoms experienced by women with breast cancer that were wrongly attributed to side effects of tamoxifen treatment had a dampening effect on medication adherence, according to a new...

...

12/13/2016

Journal of Clinical Pathways